Pathophysiological characteristics and responsiveness to neurohormonal antagonism in idiopathic dilated cardiomyopathy patients with antihepatitis C virus antibody

International Heart Journal

Volumn 46, Issue 3, 2005, Pages 407-417

  Kawai, Keisuke ^a,c   Hata, Katsuya ^a   Kawai, Hiroya ^a   Takaoka, Hideyuki ^a   Miyata Fukuoka, Yoko ^a   Okubo, Hideaki ^b   Yokoyama, Mitsuhiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Konan Hospital Foundation Rokko Island Hospital   (Japan)

^c Department of Internal Medicine   (Japan)

Author keywords

Cardiac ventricular remodeling; Heart failure; Prevalence; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPATITIS C ANTIBODY; METOPROLOL; NEUROHORMONE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CARDIOVASCULAR PARAMETERS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG RESPONSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC SIZE; HEART LEFT VENTRICLE ENDSYSTOLIC SIZE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE BIOPSY; HEART SIZE; HEART VENTRICLE CONTRACTION; HEART VENTRICLE REMODELING; HEPATITIS C; HEPATITIS C VIRUS; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL; BLOOD; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PREVALENCE; VIROLOGY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOMYOPATHY, DILATED; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; PREVALENCE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 26044454586     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.46.407     Document Type: Article

References (33)

1. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 1995; 92: 2519-25.
2. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351-5. (Review)
3. Okabe M, Fukuda K, Arakawa K, Kikuchi M. Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation 1997; 96: 22-4.
4. Frustaci A, Calabrese F, Chimenti C, Pieroni M, Thiene G, Maseri A. Lone hepatitis C virus myocarditis responsive to immunosuppressive therapy. Chest 2002; 122: 1348-56.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
6. Tendera M, Ochala A. Overview of the results of recent beta blocker trials. Curr Opin Cardiol 2001; 16: 180-5. (Review)
7. Lechat P, Escolano S, Golmard JI, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1997; 96: 2197-205.
8. Kawai K, Takaoka H, Hata K, Yokota Y, Yokoyama M. Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 84: 671-6.
9. Moriya T, Koyama T, Tanaka J, Mishiro S, Yoshizawa H. Epidemiology of hepatitis C virus in Japan. Intervirology 1999; 42: 153-8.
10. Matsumori A, Ohashi N. Hasegawa K, et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Cire J 1998; 62: 389-91.
11. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93: 841-2.
12. Teragaki M, Nishiguchi S, Takeuchi K, Yoshiyama M, Akioka K, Yoshikawa J. Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. Heart Vessels 2003; 18: 167-70.
13. Sekiguchi M, Hiroe M, Morimoto S. On the standardization of histopathological diagnosis and semiquantitative assessment of the endo-myocardium obtained by endomyocardial biopsy. Bull Heart Inst Japan 1979/80; 21: 55-85.
14. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
15. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-83.
16. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-8.
17. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta blocker therapy: a potential of hormone-guided treatment. Am Heart J 2001; 141: 925-32.
18. Tanaka H, Hiyama T, Tsukuma H, et al. Prevalence of second generation antibody to hepatitis C virus among voluntary blood donors in Osaka, Japan. Cancer Causes Control 1994; 5: 409-13.
19. Prati D, Poli F, Farma E, et al. Multicenter study on hepatitis C virus infection in patients with dilated cardiomyopathy. North Italy Transplant Program (NITP). J Med Virol 1999; 58: 116-20.
20. Grumbach IM, Heermann K, Figulla HR, Low prevalence of hepatitis C virus antibodies and RNA in patients with myocarditis and dilated cardiomyopathy. Cardiology 1998; 90: 75-8.
21. Dalekos GN, Achenbach K, Christodoulou D, et al. Idiopathic dilated cardiomyopathy: lack of association with hepatitis C virus infection. Heart 1998; 80: 270-5.
22. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-70.
23. Matsumori A, Matoba Y, Nishio R, Shioi T, Ono Y, Sasayama S. Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 1996; 222: 678-82.
24. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus serospositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359: 133-5.
25. Takeda A, Sakata A, Takeda N. Detection of hepatitis C virus RNA in the hearts of patients with hepatogenic cardiomyopathy. Mol Cell Biochem 1999; 195: 257-61.
26. Yan FM, Chen AS, Hao F, et al. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol 2000; 6: 805-11.
27. Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N, Shimotohno K. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology 1999; 258: 100-7.
28. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74.
29. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-6.
30. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 99: 557-61.(Review)
31. Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996; 37: 905-15.
32. Sartori M, Andorno S, La Terra G, et al. Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiography. Eur J Clin Invest 1995; 25: 68-70.
33. Saeki A, Goto Y, Hata K, Takasago T, Nishioka T, Suga H. Negative inotropism of hyperthermia increases oxygen cost of contractility in canine hearts. Am J Physiol Heart Circ Physiol 2000; 279: H2855-64.